PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1178506
PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1178506
The Europe lung cancer diagnostics market is projected to register a substantial CAGR of 13.3% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030
Europe Lung Cancer Diagnostics Market, By Product Type (Instruments, Consumables & Accessories), Test Type (Biomarkers Test, Imaging Test, Biopsy, Blood Test, and Others), Cancer Type (Non-Small Cell Lung Cancer, Small Cell Lung Cancer), End User (Hospital, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, and Others), Distribution Channel (Direct Tender, Retail Sales), Country (Germany, France, U.K, Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Rest of Europe) Industry Trends and Forecast to 2030.
Rise in market players and the availability of advanced services
Increase in awareness about the lung cancer diagnostics
F. Hoffmann-La Roche Ltd.
Thermo Fisher Scientific Inc.
Abbott
Quest Diagnostics Incorporated
Bio-Rad Laboratories, Inc.
Biocartis
Danaher
DiaSorin S.p.A.
Exact Sciences UK, Ltd. (a subsidiary of Exact Science Corporation)
Inivata Ltd.
Myriad Genetics, Inc.
NeoGenomics Laboratories
PerkinElmer Inc.
Vela Diagnostics
QIAGEN
Siemens Healthcare GmbH
Veracyte, Inc.